Vor Current Deferred Revenue from 2010 to 2025

VOR Stock  USD 0.77  0.04  4.94%   
Vor Biopharma Current Deferred Revenue yearly trend continues to be relatively stable with very little volatility. Current Deferred Revenue is likely to drop to about 5.1 M. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
7.3 M
Current Value
5.1 M
Quarterly Volatility
2.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vor Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vor Biopharma's main balance sheet or income statement drivers, such as Net Interest Income of 4.5 M, Interest Income of 4.5 M or Depreciation And Amortization of 3.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.75. Vor financial statements analysis is a perfect complement when working with Vor Biopharma Valuation or Volatility modules.
  
Check out the analysis of Vor Biopharma Correlation against competitors.
To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.

Latest Vor Biopharma's Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Vor Biopharma over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Vor Biopharma's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vor Biopharma's overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

Vor Current Deferred Revenue Regression Statistics

Arithmetic Mean3,536,201
Geometric Mean2,698,324
Coefficient Of Variation71.49
Mean Deviation2,398,726
Median1,404,000
Standard Deviation2,527,971
Sample Variance6.4T
Range5.9M
R-Value0.84
Mean Square Error2T
R-Squared0.71
Significance0.000041
Slope447,611
Total Sum of Squares95.9T

Vor Current Deferred Revenue History

20255.1 M
20247.3 M
20216.3 M
20196.3 M

About Vor Biopharma Financial Statements

Vor Biopharma shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Vor Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Vor Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vor Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue7.3 M5.1 M

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.